The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform

Takatsugu Okegawa - One of the best experts on this subject based on the ideXlab platform.

  • Development of nomogram to non-steroidal Antiandrogen sequential alternation in prostate cancer for predictive model.
    Japanese journal of clinical oncology, 2014
    Co-Authors: Naoto Kamiya, Hiroyoshi Suzuki, Takatsugu Okegawa, Kensaku Nishimura, Motohiro Fujii, Tadashi Matsuda, Tatsuo Morita, Yoshio Takihana, Seiichiro Ozono, Mikio Namiki
    Abstract:

    Objectives: To clarify clinical predictors for a prostate-specific antigen decrease � 50% in response to alternative non-steroidal Antiandrogen Therapy and to develop a nomogram to predict the prostate-specific antigen decrease � 50% in response to alternative non-steroidal Antiandrogen Therapy in patients with advanced prostate cancer that relapsed after initial combined androgen blockade. We previously reported that combined androgen blockade with an alternative non-steroidal Antiandrogen is effective for advanced prostate cancer that has relapsed after initial combined androgen blockade. Methods: We enrolled 161 patients from 14 medical institutions with histologically confirmed prostate cancer who had been treated with combination Therapy and in whom cancer progressed after first-line combined androgen blockade Therapy. A nomogram for the prostatespecific antigen decrease � 50% from baseline prostate-specific antigen in response to alternative non-steroidal Antiandrogen Therapy was developed based on the final logistic regression model. Results: Overall prostate-specific antigen decreased � 50% in 75 of 161 patients (46.6%) in response to alternative non-steroidal Antiandrogen Therapy. Using five independent risk factors (initial serum level of prostate-specific antigen, hemoglobin, C-reactive protein, prostate-specific antigen nadir to second hormone Therapy and Gleason sum), a nomogram was developed for the prediction of prostate-specific antigen decrease � 50% in response to alternative nonsteroidal Antiandrogen Therapy. The receiver operating characteristic curve showed that the accuracy of the predicted probability was 72.5% for the model. Conclusions: This predictive nomogram could predict the prostate-specific antigen decrease � 50% in response to alternative non-steroidal Antiandrogen Therapy and might be of benefit to determine the sequential treatment strategy in patients with relapse after first combined androgen blockade.

  • alternative Antiandrogen Therapy in patients with castration resistant prostate cancer a single center experience
    International Journal of Urology, 2010
    Co-Authors: Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara
    Abstract:

    Outcomes of alternative (second-line) Antiandrogen Therapy in 112 patients with relapsing prostate cancer after first-line hormonal Therapy were analyzed. A good response (prostate-specific antigen [PSA] decrease 50%) and a partial response (PSA decrease of 0–50%) by switching from bicalutamide (BCL) to flutamide (FLT) and from FLT to BCL were achieved in 35.4% (28/79) and 30.4% (24/79), and in 45.0% (9/20) and 20.0% (4/20) of cases, respectively. A good response and a partial response with the change from chlormadinone acetate (CMA) to a non-steroidal Antiandrogen (FLT or BCL)and from a non-steroidal Antiandrogen to CMA were obtained in 25.0% (2/8) and 37.5% (3/8), and in 20.0% (1/5) and 0% (0/5)of cases, respectively. In multivariate analyses, a second-line good response was significantly predictive of cause-specific survival from first Therapy relapse to cancer death in all patients. Patients (52/112, 46.4%) with 30% decrease in PSA levels were associated with significantly better cause-specific survival as measured from the start of first-line treatment and first-line relapse.

  • Alternative Antiandrogen Therapy in patients with castration‐resistant prostate cancer: A single‐center experience
    International journal of urology : official journal of the Japanese Urological Association, 2010
    Co-Authors: Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara
    Abstract:

    Outcomes of alternative (second-line) Antiandrogen Therapy in 112 patients with relapsing prostate cancer after first-line hormonal Therapy were analyzed. A good response (prostate-specific antigen [PSA] decrease 50%) and a partial response (PSA decrease of 0–50%) by switching from bicalutamide (BCL) to flutamide (FLT) and from FLT to BCL were achieved in 35.4% (28/79) and 30.4% (24/79), and in 45.0% (9/20) and 20.0% (4/20) of cases, respectively. A good response and a partial response with the change from chlormadinone acetate (CMA) to a non-steroidal Antiandrogen (FLT or BCL)and from a non-steroidal Antiandrogen to CMA were obtained in 25.0% (2/8) and 37.5% (3/8), and in 20.0% (1/5) and 0% (0/5)of cases, respectively. In multivariate analyses, a second-line good response was significantly predictive of cause-specific survival from first Therapy relapse to cancer death in all patients. Patients (52/112, 46.4%) with 30% decrease in PSA levels were associated with significantly better cause-specific survival as measured from the start of first-line treatment and first-line relapse.

Eiji Higashihara - One of the best experts on this subject based on the ideXlab platform.

  • alternative Antiandrogen Therapy in patients with castration resistant prostate cancer a single center experience
    International Journal of Urology, 2010
    Co-Authors: Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara
    Abstract:

    Outcomes of alternative (second-line) Antiandrogen Therapy in 112 patients with relapsing prostate cancer after first-line hormonal Therapy were analyzed. A good response (prostate-specific antigen [PSA] decrease 50%) and a partial response (PSA decrease of 0–50%) by switching from bicalutamide (BCL) to flutamide (FLT) and from FLT to BCL were achieved in 35.4% (28/79) and 30.4% (24/79), and in 45.0% (9/20) and 20.0% (4/20) of cases, respectively. A good response and a partial response with the change from chlormadinone acetate (CMA) to a non-steroidal Antiandrogen (FLT or BCL)and from a non-steroidal Antiandrogen to CMA were obtained in 25.0% (2/8) and 37.5% (3/8), and in 20.0% (1/5) and 0% (0/5)of cases, respectively. In multivariate analyses, a second-line good response was significantly predictive of cause-specific survival from first Therapy relapse to cancer death in all patients. Patients (52/112, 46.4%) with 30% decrease in PSA levels were associated with significantly better cause-specific survival as measured from the start of first-line treatment and first-line relapse.

  • Alternative Antiandrogen Therapy in patients with castration‐resistant prostate cancer: A single‐center experience
    International journal of urology : official journal of the Japanese Urological Association, 2010
    Co-Authors: Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara
    Abstract:

    Outcomes of alternative (second-line) Antiandrogen Therapy in 112 patients with relapsing prostate cancer after first-line hormonal Therapy were analyzed. A good response (prostate-specific antigen [PSA] decrease 50%) and a partial response (PSA decrease of 0–50%) by switching from bicalutamide (BCL) to flutamide (FLT) and from FLT to BCL were achieved in 35.4% (28/79) and 30.4% (24/79), and in 45.0% (9/20) and 20.0% (4/20) of cases, respectively. A good response and a partial response with the change from chlormadinone acetate (CMA) to a non-steroidal Antiandrogen (FLT or BCL)and from a non-steroidal Antiandrogen to CMA were obtained in 25.0% (2/8) and 37.5% (3/8), and in 20.0% (1/5) and 0% (0/5)of cases, respectively. In multivariate analyses, a second-line good response was significantly predictive of cause-specific survival from first Therapy relapse to cancer death in all patients. Patients (52/112, 46.4%) with 30% decrease in PSA levels were associated with significantly better cause-specific survival as measured from the start of first-line treatment and first-line relapse.

Donald L. Trump - One of the best experts on this subject based on the ideXlab platform.

  • Immediate hormonal Therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
    The New England journal of medicine, 1999
    Co-Authors: Edward M. Messing, Michael F Sarosdy, Judith Manola, George Wilding, E. David Crawford, Donald L. Trump
    Abstract:

    Background Because the optimal timing of the institution of Antiandrogen Therapy for prostate cancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after radical prostatectomy. Methods Ninety-eight men who underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metastases were randomly assigned to receive immediate Antiandrogen Therapy, with either goserelin, a synthetic agonist of gonadotropin-releasing hormone, or bilateral orchiectomy, or to be followed until disease progression. The patients were assessed quarterly during the first year and then semiannually. Results After a median of 7.1 years of follow-up, 7 of 47 men who received immediate Antiandrogen treatment had died, as compared with 18 of 51 men in the observation group (P=0.02). The cause of death was prostate cancer in 3 men in the immediate-treatment group and in 16 men in the observation group (P

  • immediate hormonal Therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer
    The New England Journal of Medicine, 1999
    Co-Authors: Edward M. Messing, Michael F Sarosdy, Judith Manola, George Wilding, David E Crawford, Donald L. Trump
    Abstract:

    Background Because the optimal timing of the institution of Antiandrogen Therapy for prostate cancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after radical prostatectomy. Methods Ninety-eight men who underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metastases were randomly assigned to receive immediate Antiandrogen Therapy, with either goserelin, a synthetic agonist of gonadotropin-releasing hormone, or bilateral orchiectomy, or to be followed until disease progression. The patients were assessed quarterly during the first year and then semiannually. Results After a median of 7.1 years of follow-up, 7 of 47 men who received immediate Antiandrogen treatment had died, as compared with 18 of 51 men in the observation group (P=0.02). The cause of death was prostate cancer in 3 men in the immediate-treatment group and in 16 men in the observation group (P<0.01). At the time of the last follow-up, 36 men...

Jurgen L Muller - One of the best experts on this subject based on the ideXlab platform.

Donald J. Cohen - One of the best experts on this subject based on the ideXlab platform.

  • Steroid hormones and Tourette's syndrome: early experience with Antiandrogen Therapy
    Journal of clinical psychopharmacology, 1994
    Co-Authors: Bradley S. Peterson, James F. Leckman, Lawrence Scahill, Frederick Naftolin, David L. Keefe, Nancy J. Charest, Robert A. King, Maureen T. Hardin, Donald J. Cohen
    Abstract:

    We report here the first use in Tourette's syndrome of the nonsteroidal androgen receptor blocking agent flutamide. One man and one woman underwent open trials of the medication, and a second man participated in a placebo-controlled, double-blind crossover trial. Improvement in tic symptoms ranged from 45 to 60%. The improvement was sustained in the woman during daily flutamide use and in one man during its intermittent use. One man's symptoms became refractory to treatment after 5 weeks of flutamide use, whereas the woman became depressed and had protracted diarrhea during her treatment.